GCP
PASG icon

GSA Capital Partners’s Passage Bio PASG Stock Holding History

GSA Capital Partners’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,509
Closed -$125K – 1835
2023
Q1 		$125K Buy
6,509
+1,167
+22% +$31.6K 0.01% 1330
2022
Q4 		$147K Buy
5,342
+1,082
+25% +$27.3K 0.02% 1250
2022
Q3 		$106K Sell
4,260
-225
-5% -$8.87K 0.01% 1354
2022
Q2 		$212K Buy
4,485
+1,083
+32% +$50.6K 0.03% 1045
2022
Q1 		$211K Buy
3,402
+2,248
+195% +$185K 0.03% 1148
2021
Q4 		$147K Buy
1,154
+55
+5% +$8.98K 0.02% 1274
2021
Q3 		$219K Buy
+1,099
New +$262K 0.02% 1192

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GSA Capital Partners's PASG Position: Q2 2023 in Review

GSA Capital Partners sold out of Passage Bio (PASG) in Q2 2023, closing a stake of 6,509 shares — an estimated $125K sold.

GSA Capital Partners first reported a position in PASG in Q3 2021 and held it in 7 quarters. The position peaked at $219K in Q3 2021. 54 funds tracked by Wall St. Rank hold PASG as of Q2 2023.

  • GSA Capital Partners reported no remaining Passage Bio position as of Q2 2023 after selling out during the quarter.
  • GSA Capital Partners sold 6,509 Passage Bio shares in Q2 2023, an estimated $125K.
  • GSA Capital Partners first reported a position in Passage Bio in Q3 2021 and held it in 7 quarters.
  • GSA Capital Partners's Passage Bio position peaked at $219K in Q3 2021.
  • 54 funds tracked by Wall St. Rank held Passage Bio as of Q2 2023.

Based on GSA Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.